A SPECIALTY PHARMACEUTICAL COMPANY
Leading the Way in Developing Cutting Edge Solutions for Complex Injectable Medicines.
scroll
A SPECIALTY PHARMACEUTICAL COMPANY
ABOUT HBT LABS
HBT Labs develops complex injectable medicines. We are a specialty pharmaceutical company focused on drugs with complex chemistry and manufacturing processes. Our pipeline includes generic and 505(b)(2) products that target various treatment indications including cancer and CNS disorders. HBT operates an FDA-inspected cGMP aseptic manufacturing facility licensed by the State of California, as well as research and development laboratories, both located in Brea, California.
More About HBT Labs
ABOUT HBT LABS
HBT Labs develops complex injectable medicines. We are a specialty pharmaceutical company focused on high barrier, parenteral generic drugs with complex chemistry and manufacturing processes. Our pipeline of drugs includes generic and 505(b)(2) products that target a variety of treatment indications, including cancer and CNS disorders.
Research and Development
HBT’s research and development efforts focus on complex injectable pharmaceutical products to treat disease, including CNS disorders and cancer. HBT has extensive experience in developing proprietary processes and technologies to produce complex drugs across multiple delivery platforms, including liposomes, nanoparticles, emulsions and long-acting injectable suspensions.
Development Projects
Research and Development
HBT’s research and development efforts focus on complex injectable pharmaceutical products to treat disease, including CNS disorders and cancer. HBT has extensive experience in developing proprietary processes and technologies to produce complex drugs across multiple delivery platforms, including liposomes, nanoparticles, emulsions and long-acting injectable suspensions.
AN EXTENSIVE PRODUCT PIPELINE
HBT received FDA approval of its Fulvestrant product (generic for Fasoldex ®) which launched in 2020. HBT has filed a New Drug Application under Section 505(b)(2) for its Paclitaxel product (generic for Abraxane ®). The company will start bioequivalence and clinical studies on three additional products for indications including CNS in 2021, and has several products in its research pipeline, including ophthalmics.
Research Projects
AN EXTENSIVE PRODUCT PIPELINE
HBT received FDA approval of its Fulvestrant product (generic for Fasoldex ®) which launched in 2020. HBT has filed a New Drug Application under Section 505(b)(2) for its Paclitaxel product (generic for Abraxane ®). The company will start bioequivalence and clinical studies on three additional products for indications including CNS in 2021, and has several products in its research pipeline, including ophthalmics.
CONTRACT, DEVELOPMENT, AND MANUFACTURING
HBT offers a broad range of contract development and manufacturing services. HBT helps develop formulations focused specifically on its drug delivery expertise and manufactures clinical supplies or early-stage products
MORE ABOUT CDMO
CONTRACT, DEVELOPMENT AND MANUFACTURING
HBT offers a broad range of contract development and manufacturing services. HBT helps develop formulations focused specifically on its drug delivery expertise and manufactures clinical supplies or early-stage products.